Head-to-head evidence
Mepolizumab vs SB-240563
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: IL-5 · full Asthma pipeline
Mepolizumab · Nucala
Marketed by GlaxoSmithKline
NCT01691859 · Phase 3 · completed
This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial.
Next expected readout: October 2026 · NCT07343661 (registry estimate)
SB-240563
Marketed by GlaxoSmithKline
NCT00292877 · Phase 2 · completed
The study randomized and double-blinded 20 participants for comparison with placebo, using a clinical primary endpoint based on prednisone reduction without clinical exacerbation. Because the registry contains no results, it is not possible to determine whether the primary endpoint was met; the small sample also limits the strength of the evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mepolizumab's landscape · SB-240563's landscape